Reports Q3 cash, cash equivalents, marketable securities and restricted cash at September 30 totaled $252.2 million compared to $302.4M as of December 31, 2022..”We continue to make significant progress bringing innovative medicines to patients in our region, including the achievement of critical clinical development and market building milestones,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. “Following our recent transaction granting development and commercial rights to BMS for mavacamten in our territories, we look forward to conducting a comprehensive strategic review aimed at realizing the value of our platform and product candidates.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LIAN:
- LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- LianBio to discuss Phase 3 LIBRA results with China NMPA
- LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023
- LianBio enters pact with Bristol Myers for Mavacamten in China, Asian markets
